TSX

Notice of Release of Barrick’s First Quarter 2024 Results

Retrieved on: 
Tuesday, April 9, 2024
Barrick Gold, TSX

TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) will release its Q1 2024 results on Wednesday, May 1, 2024.

Key Points: 
  • TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) will release its Q1 2024 results on Wednesday, May 1, 2024.
  • President and CEO Mark Bristow will host a live presentation of the results that day at 11:00 EDT, with an interactive webinar linked to a conference call.
  • The company will release its preliminary production, sales and cost information for Q1 2024 on April 16, 2024.
  • Release of Q1 preliminary production, sales and cost information

Talisker Signs Milling Agreement with Nicola Mining Inc.

Retrieved on: 
Tuesday, April 9, 2024
Agreement, Bralorne, TSX, OTCQX, Nicola, Talisker

TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that the Company, through its 100% owned subsidiary, Bralorne Gold Mines Ltd., has signed a milling agreement (the “Agreement”) with Nicola Mining Inc. (“Nicola”).

Key Points: 
  • TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that the Company, through its 100% owned subsidiary, Bralorne Gold Mines Ltd., has signed a milling agreement (the “Agreement”) with Nicola Mining Inc. (“Nicola”).
  • As part of the Agreement, Nicola will process up to 6,300 tonnes of stockpile mined at the Bralorne Gold Project and process it at Nicola’s Craigmont Mill located in Merritt, British Columbia.
  • Terry Harbort, Talisker’s President and CEO commented, “This Agreement with Nicola gives Talisker increased flexibility and contingency for our upcoming ore processing from the Mustang Mine at Bralorne.
  • We are pleased to be working with Peter and his professional team in the near future.”

Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results

Retrieved on: 
Tuesday, April 9, 2024
Diamond, MedMen, CPG, SweetWater Brewing Company, Blue Point Brewing Company, Craft, Cannabis, Weather, TLRY, Minhas Craft Brewery, Acquisition, Metro New York, Adjustment, TSX, Highball, Drink, Oil, Wellness, Shock, Anheuser-Busch, Beer, Advertising, Prior, Conference, Breckenridge Brewery, Growth, Environment, Tilray, Snack, Pacific Northwest, Drug

ET Today

Key Points: 
  • ET Today
    NEW YORK and LEAMINGTON, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today reported financial results for its third quarter ended February 29, 2024.
  • Beverage-alcohol gross profit increased 89% to $18.9 million in the third quarter from $10.0 million in the prior year quarter.
  • Completed Canadian cannabis business cost reduction plan launched during fiscal year 2022 and international cannabis business plan launched during fiscal year 2023.
  • For its fiscal year ending May 31, 2024, the Company is now guiding to an Adjusted EBITDA target of $60 million to $63 million.

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

Retrieved on: 
Tuesday, April 9, 2024
HER2, ILD, CPI, Survival, Progression-free survival, Central nervous system, Patient, CNS, History, Death, Eribulin, Spacecraft, MD, CBR, TPC, EMBRACE, Life, BCT, AACR, TSX, Therapy, Breast cancer, Safety, Poster, CMO, PFS, ADC, PD-1, Pharmaceutical industry

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.

Key Points: 
  • “ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.
  • To our knowledge, there are no effective treatment options in this patient population for whom the progression-free survival prognosis is only a few weeks.
  • BriaCell will be monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT™ and CPI in advanced metastatic breast cancer.
  • Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study.

Emerging Markets Report: Follow the Leader

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Disease, Biomedical Research, Patient, HPC, Health care, Artificial intelligence, NVDA, AI, WELL, A.I, TSX, Inflammatory bowel disease, Love, NVIDIA, Map, AIDX, Medicine, Medical device

ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- For some time now the market has been in love with Nvidia (NVDA), the behemoth stock which has been to say the least, a bell cow for the market. And while we don’t discuss actual share prices in our pages, preferring to focus instead on the items that historically drive favorable valuations, Nvidia’s price appreciation has been remarkable and is, powered by their revenue growth and the public’s attraction to Artificial Intelligence technology.

Key Points: 
  • And we believe that the intersection of Health Care and Artificial Intelligence is the first half of that formula.
  • With NVIDIA, healthcare institutions can harness the power of AI and high-performance computing (HPC) to define the future of medicine.
  • If the revenue trend continues, analysts, partners, and market interests may follow.
  • And HEALWELL is certainly following the leader, acquiring and developing potentially lucrative Healthcare A.I.

Titan Mining Provides Initial Drill Results on the Kilbourne Graphite Project, Results Include 173.5 ft at 3.75% Graphitic Carbon

Retrieved on: 
Tuesday, April 9, 2024
Titan, TI, Graphite, TSX, RDI, Uranium mining

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Titan Mining Corporation (TSX:TI) (“Titan” or the “Company”) is pleased to provide an update on the ongoing Kilbourne exploration program.

Key Points: 
  • VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Titan Mining Corporation (TSX:TI) (“Titan” or the “Company”) is pleased to provide an update on the ongoing Kilbourne exploration program.
  • The Company has received assays from the initial phase of trenching and from the initial fifteen drill holes of the Company’s ongoing graphite exploration program.
  • Titan CEO Don Taylor commented, “We are very pleased with the results of the initial programs.
  • The assay results have continued to exceed expectations, with the grade of mineralized drill intercepts averaging 3.2% Cg (graphitic carbon).

Calibre’s Q1 Gold Production on Track to Deliver Full Year 2024 Guidance While Advancing Operational Readiness For H1, 2025 First Gold at The Fully Funded Valentine Gold Mine

Retrieved on: 
Tuesday, April 9, 2024
Consolidated, Growth, Gold, ETW, Acquisition, Indication (medicine), TSX, Mineral, CXB, OTCQX, VGM, Process, Reserve, Van Eck, Palladium

We remain on track to deliver full year 2024 production guidance of 275,000 – 300,000 ounces.

Key Points: 
  • We remain on track to deliver full year 2024 production guidance of 275,000 – 300,000 ounces.
  • Since becoming a gold producer during Q4, 2019, Calibre has delivered annual production growth of 28% year on year, with a track record of meeting or beating expectations.
  • 2024 and 2025 will be transformational years, driven by an increase in gold production and significant exploration across the Americas.
  • I am pleased to report the final phases of construction and operational readiness remain on track and fully funded at VGM in preparation for first gold production in H1, 2025 to unlock significant production growth and value for our shareholders.

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Tuesday, April 9, 2024
Metro Toronto Convention Centre, Conference, TSX, Webcast

TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.

Key Points: 
  • TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.
  • The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Tuesday, April 9, 2024
Metro Toronto Convention Centre, GUD, TSX, Conference

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m.

Key Points: 
  • MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m.
  • ET at the Metro Toronto Convention Centre in Toronto.
  • A copy of the presentation will be available at www.knighttx.com .

Endeavour Silver Delivers Strong Production in Q1 2024

Retrieved on: 
Tuesday, April 9, 2024
Silver, Gold, Inventory, EDR, Ventilation, TSX, Guanaceví, Mining

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to report first quarter 2024 production of 1,460,006 silver ounces (oz) and 10,133 gold oz, for silver equivalent (1) (“AgEq”) production of 2.3 million oz.

Key Points: 
  • VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to report first quarter 2024 production of 1,460,006 silver ounces (oz) and 10,133 gold oz, for silver equivalent (1) (“AgEq”) production of 2.3 million oz.
  • Consolidated silver production decreased by 10% to 1,460,006 ounces in Q1 2024 compared to Q1 2023, driven by 7% lower silver production at the Guanaceví mine and 32% lower silver production at the Bolañitos mine.
  • Gold production increased by 8% to 10,133 ounces in Q1 2024 compared to Q1 2023 due to 17% higher gold production at the Bolañitos mine, offset by 2% lower gold production at the Guanaceví mine.
  • Bolañitos Q1 2024 throughput was 2% lower than Q1 2023 with 31% lower silver grades offset by 14% higher gold grades.